OPN 019
Alternative Names: OPN-019Latest Information Update: 28 Sep 2024
Price :
$50 *
At a glance
- Originator OptiNose
- Class Antiseptics; Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for phase-I development in COVID-2019-infections in Mexico (Intranasal)
- 28 Jul 2024 No recent reports of development identified for research development in COVID-2019-infections in USA (Intranasal)
- 28 Jul 2024 No recent reports of development identified for research development in COVID-2019-infections(Prevention) in USA (Intranasal)